JP2006051019A - Ｍｅ−５、ｍｅ−２、及びｅｐｐ２：子宮内膜症に罹患している女性の血清中に存在する自己抗体と反応するヒト蛋白質抗原 - Google Patents
Ｍｅ−５、ｍｅ−２、及びｅｐｐ２：子宮内膜症に罹患している女性の血清中に存在する自己抗体と反応するヒト蛋白質抗原 Download PDFInfo
- Publication number
- JP2006051019A JP2006051019A JP2005197432A JP2005197432A JP2006051019A JP 2006051019 A JP2006051019 A JP 2006051019A JP 2005197432 A JP2005197432 A JP 2005197432A JP 2005197432 A JP2005197432 A JP 2005197432A JP 2006051019 A JP2006051019 A JP 2006051019A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- endometriosis
- antibody
- polypeptide
- epitope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000009273 Endometriosis Diseases 0.000 title claims abstract description 206
- 210000002966 serum Anatomy 0.000 title claims abstract description 59
- 102000036639 antigens Human genes 0.000 title abstract description 109
- 108091007433 antigens Proteins 0.000 title abstract description 109
- 239000000427 antigen Substances 0.000 title abstract description 108
- 108090000144 Human Proteins Proteins 0.000 title description 2
- 102000003839 Human Proteins Human genes 0.000 title description 2
- 210000004696 endometrium Anatomy 0.000 claims abstract description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 100
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 94
- 229920001184 polypeptide Polymers 0.000 claims description 91
- 238000000034 method Methods 0.000 claims description 64
- 239000000523 sample Substances 0.000 claims description 56
- 239000002773 nucleotide Substances 0.000 claims description 55
- 125000003729 nucleotide group Chemical group 0.000 claims description 55
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 34
- 150000001413 amino acids Chemical class 0.000 claims description 30
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 25
- 201000010099 disease Diseases 0.000 claims description 23
- 238000003745 diagnosis Methods 0.000 claims description 22
- 108091033319 polynucleotide Proteins 0.000 claims description 21
- 102000040430 polynucleotide Human genes 0.000 claims description 21
- 239000002157 polynucleotide Substances 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 17
- 230000009870 specific binding Effects 0.000 claims description 12
- 238000001514 detection method Methods 0.000 claims description 11
- 239000013068 control sample Substances 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 abstract description 218
- 102000004169 proteins and genes Human genes 0.000 abstract description 198
- 238000003556 assay Methods 0.000 abstract description 12
- 235000018102 proteins Nutrition 0.000 description 192
- 210000004027 cell Anatomy 0.000 description 66
- 210000001519 tissue Anatomy 0.000 description 64
- 239000002299 complementary DNA Substances 0.000 description 58
- 241000238631 Hexapoda Species 0.000 description 56
- 230000009257 reactivity Effects 0.000 description 56
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 54
- 230000014509 gene expression Effects 0.000 description 47
- 238000001262 western blot Methods 0.000 description 40
- 108091026890 Coding region Proteins 0.000 description 31
- 230000002357 endometrial effect Effects 0.000 description 25
- 238000002474 experimental method Methods 0.000 description 25
- 239000003550 marker Substances 0.000 description 25
- 108020004999 messenger RNA Proteins 0.000 description 25
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 24
- 235000001014 amino acid Nutrition 0.000 description 23
- 239000006166 lysate Substances 0.000 description 23
- 229940024606 amino acid Drugs 0.000 description 22
- 238000000636 Northern blotting Methods 0.000 description 21
- 238000001597 immobilized metal affinity chromatography Methods 0.000 description 21
- 150000007523 nucleic acids Chemical class 0.000 description 21
- 241000701447 unidentified baculovirus Species 0.000 description 21
- 239000013592 cell lysate Substances 0.000 description 20
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 20
- 239000013598 vector Substances 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 239000000499 gel Substances 0.000 description 18
- 108020004705 Codon Proteins 0.000 description 16
- 238000003119 immunoblot Methods 0.000 description 16
- 239000000872 buffer Substances 0.000 description 15
- 238000010186 staining Methods 0.000 description 15
- 102000039446 nucleic acids Human genes 0.000 description 14
- 108020004707 nucleic acids Proteins 0.000 description 14
- 239000011347 resin Substances 0.000 description 14
- 229920005989 resin Polymers 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 12
- 108091008146 restriction endonucleases Proteins 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 238000009396 hybridization Methods 0.000 description 11
- 210000001550 testis Anatomy 0.000 description 11
- 210000001072 colon Anatomy 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 10
- 229920002684 Sepharose Polymers 0.000 description 9
- 108091081024 Start codon Proteins 0.000 description 9
- 239000012148 binding buffer Substances 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 210000002307 prostate Anatomy 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000012546 transfer Methods 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 8
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 8
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 238000002955 isolation Methods 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 8
- 210000000813 small intestine Anatomy 0.000 description 8
- 206010003445 Ascites Diseases 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 description 7
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 210000005259 peripheral blood Anatomy 0.000 description 7
- 239000011886 peripheral blood Substances 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 6
- 238000012408 PCR amplification Methods 0.000 description 6
- 108091036066 Three prime untranslated region Proteins 0.000 description 6
- 238000002869 basic local alignment search tool Methods 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 210000001541 thymus gland Anatomy 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 238000011144 upstream manufacturing Methods 0.000 description 6
- 210000004291 uterus Anatomy 0.000 description 6
- -1 AEBP-1 Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 5
- 239000012491 analyte Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000002357 laparoscopic surgery Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 239000011534 wash buffer Substances 0.000 description 5
- 108020004635 Complementary DNA Proteins 0.000 description 4
- 101000623061 Drosophila melanogaster 40S ribosomal protein S26 Proteins 0.000 description 4
- 101000608720 Helianthus annuus 10 kDa late embryogenesis abundant protein Proteins 0.000 description 4
- 101000608734 Helianthus annuus 11 kDa late embryogenesis abundant protein Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 4
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 description 4
- 238000012300 Sequence Analysis Methods 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000004392 genitalia Anatomy 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 208000000509 infertility Diseases 0.000 description 4
- 230000036512 infertility Effects 0.000 description 4
- 231100000535 infertility Toxicity 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 108091093088 Amplicon Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 206010014733 Endometrial cancer Diseases 0.000 description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- VEQPNABPJHWNSG-UHFFFAOYSA-N Nickel(2+) Chemical compound [Ni+2] VEQPNABPJHWNSG-UHFFFAOYSA-N 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 108091005461 Nucleic proteins Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 238000012761 co-transfection Methods 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000012149 elution buffer Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 208000026278 immune system disease Diseases 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 230000002175 menstrual effect Effects 0.000 description 3
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 3
- 229910052759 nickel Inorganic materials 0.000 description 3
- 229910001453 nickel ion Inorganic materials 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 3
- 238000011020 pilot scale process Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010036652 HSC70 Heat-Shock Proteins Proteins 0.000 description 2
- 102000012215 HSC70 Heat-Shock Proteins Human genes 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 208000037093 Menstruation Disturbances Diseases 0.000 description 2
- 101100288960 Mus musculus Lefty1 gene Proteins 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 2
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 206010065951 Retrograde menstruation Diseases 0.000 description 2
- 208000016599 Uterine disease Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 239000010836 blood and blood product Substances 0.000 description 2
- 229940125691 blood product Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000003756 cervix mucus Anatomy 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 208000011099 endometrial disease Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002992 thymic effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- 102100033714 40S ribosomal protein S6 Human genes 0.000 description 1
- ODPOAESBSUKMHD-UHFFFAOYSA-L 6,7-dihydrodipyrido[1,2-b:1',2'-e]pyrazine-5,8-diium;dibromide Chemical compound [Br-].[Br-].C1=CC=[N+]2CC[N+]3=CC=CC=C3C2=C1 ODPOAESBSUKMHD-UHFFFAOYSA-L 0.000 description 1
- 102100033824 A-kinase anchor protein 12 Human genes 0.000 description 1
- 101710148586 ADP,ATP carrier protein 1 Proteins 0.000 description 1
- 101710111394 ADP,ATP carrier protein 1, mitochondrial Proteins 0.000 description 1
- 101710102716 ADP/ATP translocase 1 Proteins 0.000 description 1
- 102100032533 ADP/ATP translocase 1 Human genes 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 108010009924 Aconitate hydratase Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 102100039075 Aldehyde dehydrogenase family 1 member A3 Human genes 0.000 description 1
- 101710192173 Aldehyde dehydrogenase family 1 member A3 Proteins 0.000 description 1
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 102100030907 Aryl hydrocarbon receptor nuclear translocator Human genes 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000510930 Brachyspira pilosicoli Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010008629 CA-125 Antigen Proteins 0.000 description 1
- 102000007269 CA-125 Antigen Human genes 0.000 description 1
- 101150071146 COX2 gene Proteins 0.000 description 1
- 101000690445 Caenorhabditis elegans Aryl hydrocarbon receptor nuclear translocator homolog Proteins 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102000003908 Cathepsin D Human genes 0.000 description 1
- 108090000258 Cathepsin D Proteins 0.000 description 1
- 108090000613 Cathepsin S Proteins 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
- 102000012272 Cholestanetriol 26-monooxygenase Human genes 0.000 description 1
- 108010022102 Cholestanetriol 26-monooxygenase Proteins 0.000 description 1
- 208000016216 Choristoma Diseases 0.000 description 1
- 102100038447 Claudin-4 Human genes 0.000 description 1
- 108090000601 Claudin-4 Proteins 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 description 1
- 101710126238 Collagen alpha-2(I) chain Proteins 0.000 description 1
- 102100033781 Collagen alpha-2(IV) chain Human genes 0.000 description 1
- 102000016918 Complement C3 Human genes 0.000 description 1
- 108010028780 Complement C3 Proteins 0.000 description 1
- 108010069241 Connexin 43 Proteins 0.000 description 1
- 102000001045 Connexin 43 Human genes 0.000 description 1
- 108010061635 Cystatin B Proteins 0.000 description 1
- 102100026891 Cystatin-B Human genes 0.000 description 1
- 102100039868 Cytoplasmic aconitate hydratase Human genes 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 239000005630 Diquat Substances 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102100029952 Double-strand-break repair protein rad21 homolog Human genes 0.000 description 1
- 102100029791 Double-stranded RNA-specific adenosine deaminase Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 1
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 1
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 1
- 102100028471 Eosinophil peroxidase Human genes 0.000 description 1
- 108091060211 Expressed sequence tag Proteins 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 102100035427 Forkhead box protein O1 Human genes 0.000 description 1
- 102000034286 G proteins Human genes 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000004878 Gelsolin Human genes 0.000 description 1
- 108090001064 Gelsolin Proteins 0.000 description 1
- 208000022555 Genital disease Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102100029880 Glycodelin Human genes 0.000 description 1
- 108010042283 HSP40 Heat-Shock Proteins Proteins 0.000 description 1
- 102000004447 HSP40 Heat-Shock Proteins Human genes 0.000 description 1
- 101150112743 HSPA5 gene Proteins 0.000 description 1
- 102100025255 Haptoglobin Human genes 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
- 101710113864 Heat shock protein 90 Proteins 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000779382 Homo sapiens A-kinase anchor protein 12 Proteins 0.000 description 1
- 101000614487 Homo sapiens Adenylate kinase 4, mitochondrial Proteins 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000793115 Homo sapiens Aryl hydrocarbon receptor nuclear translocator Proteins 0.000 description 1
- 101000710876 Homo sapiens Collagen alpha-2(IV) chain Proteins 0.000 description 1
- 101000861034 Homo sapiens Cytochrome c oxidase subunit 3 Proteins 0.000 description 1
- 101000584942 Homo sapiens Double-strand-break repair protein rad21 homolog Proteins 0.000 description 1
- 101000865408 Homo sapiens Double-stranded RNA-specific adenosine deaminase Proteins 0.000 description 1
- 101000877727 Homo sapiens Forkhead box protein O1 Proteins 0.000 description 1
- 101000998053 Homo sapiens GTP:AMP phosphotransferase AK3, mitochondrial Proteins 0.000 description 1
- 101000585553 Homo sapiens Glycodelin Proteins 0.000 description 1
- 101001078385 Homo sapiens Haptoglobin Proteins 0.000 description 1
- 101000866657 Homo sapiens Hsp70-binding protein 1 Proteins 0.000 description 1
- 101000606465 Homo sapiens Inactive tyrosine-protein kinase 7 Proteins 0.000 description 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 1
- 101001095231 Homo sapiens Peptidyl-prolyl cis-trans isomerase D Proteins 0.000 description 1
- 101000612134 Homo sapiens Procollagen C-endopeptidase enhancer 1 Proteins 0.000 description 1
- 101001098833 Homo sapiens Proprotein convertase subtilisin/kexin type 6 Proteins 0.000 description 1
- 101000617823 Homo sapiens Solute carrier organic anion transporter family member 6A1 Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 102100031716 Hsp70-binding protein 1 Human genes 0.000 description 1
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 1
- 108050009527 Hypoxia-inducible factor-1 alpha Proteins 0.000 description 1
- 102100029620 Immunoglobulin lambda constant 2 Human genes 0.000 description 1
- 108010004020 Immunoglobulin lambda-Chains Proteins 0.000 description 1
- 102100039813 Inactive tyrosine-protein kinase 7 Human genes 0.000 description 1
- 102000004372 Insulin-like growth factor binding protein 2 Human genes 0.000 description 1
- 108090000964 Insulin-like growth factor binding protein 2 Proteins 0.000 description 1
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 description 1
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 101710192606 Latent membrane protein 2 Proteins 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 108700036248 MT-RNR1 Proteins 0.000 description 1
- 108010076502 Matrix Metalloproteinase 11 Proteins 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000006746 NADH Dehydrogenase Human genes 0.000 description 1
- 108010086428 NADH Dehydrogenase Proteins 0.000 description 1
- 108091008747 NR2F3 Proteins 0.000 description 1
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102100041026 Procollagen C-endopeptidase enhancer 1 Human genes 0.000 description 1
- 102100038946 Proprotein convertase subtilisin/kexin type 6 Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710115194 Protease inhibitor 1 Proteins 0.000 description 1
- 102100028588 Protein ZNRD2 Human genes 0.000 description 1
- 108090000944 RNA Helicases Proteins 0.000 description 1
- 102000004409 RNA Helicases Human genes 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 102100025234 Receptor of activated protein C kinase 1 Human genes 0.000 description 1
- 108010044157 Receptors for Activated C Kinase Proteins 0.000 description 1
- 108090000221 Ribosomal protein S6 Proteins 0.000 description 1
- 101100111629 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KAR2 gene Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
- 102000017303 Stromelysin-3 Human genes 0.000 description 1
- 101710119418 Superoxide dismutase [Mn] Proteins 0.000 description 1
- 101710202572 Superoxide dismutase [Mn], mitochondrial Proteins 0.000 description 1
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101710109576 Terminal protein Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000011409 Transcobalamins Human genes 0.000 description 1
- 108010023603 Transcobalamins Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 108050008367 Transmembrane emp24 domain-containing protein 7 Proteins 0.000 description 1
- 101710128947 Tricarboxylate transport protein, mitochondrial Proteins 0.000 description 1
- 102100036216 Tricarboxylate transport protein, mitochondrial Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229960000766 danazol Drugs 0.000 description 1
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012774 diagnostic algorithm Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 101150028578 grp78 gene Proteins 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000055252 human PPID Human genes 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 235000020130 leben Nutrition 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 108091016323 lipid binding proteins Proteins 0.000 description 1
- 102000019758 lipid binding proteins Human genes 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 108010008217 nidogen Proteins 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 108010090916 phospholipase C epsilon Proteins 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 102000004401 podocalyxin Human genes 0.000 description 1
- 108090000917 podocalyxin Proteins 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 238000012514 protein characterization Methods 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000012340 reverse transcriptase PCR Methods 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000225 tumor suppressor protein Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/364—Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/811—Drug, bio-affecting and body treating compositions involving sex selection or contraception
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/85—Reproductive organs or embryos
- Y10S530/852—Sperm
- Y10S530/853—Ovary; eggs; embryos
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Biotechnology (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Pregnancy & Childbirth (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/887,540 US20060008876A1 (en) | 2004-07-07 | 2004-07-07 | ME-5, ME-2, and EPP2: human protein antigens reactive with autoantibodies present in the serum of women suffering from endometriosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006051019A true JP2006051019A (ja) | 2006-02-23 |
| JP2006051019A5 JP2006051019A5 (OSRAM) | 2007-07-12 |
Family
ID=35124497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005197432A Pending JP2006051019A (ja) | 2004-07-07 | 2005-07-06 | Ｍｅ−５、ｍｅ−２、及びｅｐｐ２：子宮内膜症に罹患している女性の血清中に存在する自己抗体と反応するヒト蛋白質抗原 |
Country Status (9)
| Country | Link |
|---|---|
| US (7) | US20060008876A1 (OSRAM) |
| EP (1) | EP1614692B1 (OSRAM) |
| JP (1) | JP2006051019A (OSRAM) |
| AT (1) | ATE433462T1 (OSRAM) |
| AU (1) | AU2005202925A1 (OSRAM) |
| CA (1) | CA2509632A1 (OSRAM) |
| DE (1) | DE602005014828D1 (OSRAM) |
| ES (1) | ES2326324T3 (OSRAM) |
| NZ (1) | NZ541063A (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8329399B2 (en) * | 2006-10-27 | 2012-12-11 | Siu K W Michael | Endometrial biomarkers |
| US8279789B2 (en) * | 2008-06-10 | 2012-10-02 | Qualcomm Incorporated | Intelligent setting of hysteresis activation timer to enter hysteresis sooner and save battery |
| US20110171291A1 (en) * | 2010-01-07 | 2011-07-14 | Sanford-Burnham Medical Research Institute | Pathologically-activated therapeutics |
| DE102012002929A1 (de) | 2012-02-14 | 2013-08-14 | Jürgen Lewald | Minimalinvasives Verfahren für die Diagnose und die Therapieverlaufskontrolle der Endometriose |
| GB202310300D0 (en) | 2023-07-05 | 2023-08-16 | Univ Edinburgh | Endometrosis markers and methods of diagnosing nedometriosis |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US652187A (en) * | 1899-11-02 | 1900-06-19 | Sigvald Krohn | System of electrical distribution. |
| US4489166A (en) * | 1982-05-27 | 1984-12-18 | Research Corporation | Monitoring of human endometrial function by radioimmunoassay of PEP |
| AU5068090A (en) | 1989-03-07 | 1990-09-13 | Adeza Biomedical Corporation | Endometriosis diagnosis methods and reagents |
| EP0530335B1 (de) | 1991-03-15 | 1996-08-14 | F. Hoffmann-La Roche Ag | Diphosphonsaurederivate als zwischenprodukte zur herstellung von diphosphinliganden |
| CA2062675A1 (en) | 1991-04-09 | 1992-10-10 | Sandra S. Fenton | Endometrial antigen, composition, test kit and method for endometrial antibody determination |
| WO1994028021A1 (en) * | 1993-05-28 | 1994-12-08 | Medical University Of South Carolina | Endometrial proteins, antigenic compositions and methods for detecting endometriosis |
| US5877284A (en) * | 1993-08-12 | 1999-03-02 | The Trustees Of The University Of Pennsylvania | Isolated chemotactic factor from patients with endometriosis |
| US6531277B2 (en) * | 1994-10-25 | 2003-03-11 | The Curators Of The University Of Missouri | Endometriosis-specific secretory protein |
| US7122322B2 (en) * | 1994-10-25 | 2006-10-17 | The Curators Of The University Of Missouri | Endometriosis-specific secretory protein |
| US5843673A (en) * | 1994-10-25 | 1998-12-01 | Curators Of The University Of Missouri | Method of screening for endometriosis |
| US5618680A (en) * | 1994-12-28 | 1997-04-08 | Institut De Medecine De La Reproduction De Montreal | Use of ligands specific to major histocompatibility complex-class I antigens for diagnosing endometriosis |
| US6376201B2 (en) * | 1994-12-28 | 2002-04-23 | Procrea Biosciences Inc. | Use of ligands specific to major histocompatibility complex-class I antigens for diagnosing endometriosis |
| WO1997035016A1 (en) | 1996-03-18 | 1997-09-25 | Novo Nordisk Biotech Inc | Polypeptides having phytase activity and nucleic acids encoding same |
| WO1997035018A1 (en) | 1996-03-21 | 1997-09-25 | New York University | Growth factor inducible serine/threonine phosphatase fin13 |
| US6294662B1 (en) * | 1996-08-27 | 2001-09-25 | University Of South Florida | Nucleic acids encoding an endometrial bleeding associated factor (ebaf) |
| JP2001516009A (ja) | 1997-07-17 | 2001-09-25 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | ガン関連核酸及びポリペプチド |
| US6165767A (en) * | 1998-03-20 | 2000-12-26 | Incyte Pharmaceuticals, Inc. | Protein phosphatase-related molecules |
| CA2299436A1 (en) | 1998-06-04 | 1999-12-09 | Reprogen, Inc. | Use of prothymosin in the diagnosis and treatment of endometriosis |
| EP1076723A2 (en) * | 1998-06-04 | 2001-02-21 | Reprogen, Inc. | Use of cathepsin s in the diagnosis and treatment of endometriosis |
| US6525187B1 (en) * | 1998-07-31 | 2003-02-25 | Diagnostic Products Corporation | Polynucleotide encoding autoantigens associated with endometriosis |
| AU2088800A (en) | 1999-01-25 | 2000-08-07 | Procrea Biosciences Inc. | Method and diagnostic kit for diagnosis of endometriosis |
| ATE260678T1 (de) * | 1999-04-02 | 2004-03-15 | Ct Molecular Med & Immunology | Verfahren zur detektion von endometriosis |
| WO2000063675A1 (en) | 1999-04-16 | 2000-10-26 | Bioincept, Inc. | Identification of a serum marker for endometriosis |
| WO2000075321A2 (en) * | 1999-06-03 | 2000-12-14 | Curagen Corporation | Polynucleotides and membrane-bound polypeptide encoded thereby |
| WO2001032920A2 (en) | 1999-11-03 | 2001-05-10 | Metris Therapeutics Limited | Agents implicated in endometriosis |
| GB0004232D0 (en) | 2000-02-24 | 2000-04-12 | Zeneca Ltd | Diagnostic method |
| DE60140580D1 (de) * | 2000-02-25 | 2009-12-31 | Siemens Healthcare Diagnostics | Endometriose Marker und Verwendung derselben |
| EP1307745A2 (en) * | 2000-04-19 | 2003-05-07 | Research Corporation Technologies, Inc | Diagnostic assay for endometriosis |
| WO2001081922A2 (en) * | 2000-04-19 | 2001-11-01 | Research Corporation Technologies, Inc. | Diagnostic assay for endometriosis |
| US6780594B2 (en) * | 2000-09-25 | 2004-08-24 | Schering Aktiengesellschaft | Method for in vitro diagnosis of endometriosis |
| DE10048633A1 (de) | 2000-09-25 | 2002-04-18 | Schering Ag | Methode zur in vitro Diagnostik von Endometriose |
| AU2002255478A1 (en) | 2001-01-10 | 2002-09-12 | Pe Corporation (Ny) | Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof |
| WO2003007685A2 (en) * | 2001-07-17 | 2003-01-30 | University Of Florida | Detecting and treating reproductive tract disorders |
| JP2006516089A (ja) * | 2002-10-02 | 2006-06-22 | ジェネンテック・インコーポレーテッド | 腫瘍の診断と治療のための組成物と方法 |
| WO2004087874A2 (en) | 2003-03-28 | 2004-10-14 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
| WO2005019258A2 (en) * | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US6843673B1 (en) * | 2004-04-30 | 2005-01-18 | Speed Tech Corp. | Coaxial connector structure |
-
2004
- 2004-07-07 US US10/887,540 patent/US20060008876A1/en not_active Abandoned
-
2005
- 2005-06-30 AT AT05254121T patent/ATE433462T1/de not_active IP Right Cessation
- 2005-06-30 EP EP05254121A patent/EP1614692B1/en not_active Expired - Lifetime
- 2005-06-30 DE DE602005014828T patent/DE602005014828D1/de not_active Expired - Lifetime
- 2005-06-30 NZ NZ541063A patent/NZ541063A/en not_active IP Right Cessation
- 2005-06-30 ES ES05254121T patent/ES2326324T3/es not_active Expired - Lifetime
- 2005-07-04 AU AU2005202925A patent/AU2005202925A1/en not_active Abandoned
- 2005-07-05 CA CA002509632A patent/CA2509632A1/en not_active Abandoned
- 2005-07-06 JP JP2005197432A patent/JP2006051019A/ja active Pending
-
2006
- 2006-11-06 US US11/593,874 patent/US20080153106A1/en not_active Abandoned
- 2006-11-06 US US11/593,693 patent/US20070141600A1/en not_active Abandoned
- 2006-11-06 US US11/593,975 patent/US20070178528A1/en not_active Abandoned
-
2009
- 2009-07-15 US US12/460,255 patent/US7879562B2/en not_active Expired - Fee Related
- 2009-07-22 US US12/460,724 patent/US7981626B2/en not_active Expired - Fee Related
-
2011
- 2011-03-03 US US13/040,130 patent/US8030007B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES2326324T3 (es) | 2009-10-07 |
| US20070178528A1 (en) | 2007-08-02 |
| EP1614692B1 (en) | 2009-06-10 |
| ATE433462T1 (de) | 2009-06-15 |
| NZ541063A (en) | 2008-07-31 |
| US20060008876A1 (en) | 2006-01-12 |
| US20080153106A1 (en) | 2008-06-26 |
| US20070141600A1 (en) | 2007-06-21 |
| US7879562B2 (en) | 2011-02-01 |
| US7981626B2 (en) | 2011-07-19 |
| US20100330696A1 (en) | 2010-12-30 |
| US20100062453A1 (en) | 2010-03-11 |
| US8030007B2 (en) | 2011-10-04 |
| DE602005014828D1 (de) | 2009-07-23 |
| CA2509632A1 (en) | 2006-01-07 |
| US20110201129A1 (en) | 2011-08-18 |
| EP1614692A3 (en) | 2006-04-05 |
| EP1614692A2 (en) | 2006-01-11 |
| AU2005202925A1 (en) | 2006-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2003087831A2 (en) | Proteins involved in breast cancer | |
| US8030007B2 (en) | Method for the detection of endometriosis using an ME-2 antigen | |
| JPH06502916A (ja) | 糖尿病自己抗体の検出方法 | |
| US20180172707A1 (en) | Diagnostic target | |
| AU3102899A (en) | Early pregnancy diagnosis using PAGS (pregnancy- associated glycoproteins) | |
| WO1994028021A1 (en) | Endometrial proteins, antigenic compositions and methods for detecting endometriosis | |
| KR0174528B1 (ko) | 암과 관련된 헵토글로빈 | |
| JP3220451B2 (ja) | ブタクサからのアレルゲン蛋白質およびそれらの使用 | |
| JPS62501563A (ja) | リウマチ性関節炎の特徴である蛋白質 | |
| JP2001501300A (ja) | ヒト子宮内膜の生化学的マーカー | |
| JPH08506658A (ja) | 切迫分娩についての危険にある女性における膜の破裂を決定するための検定方法 | |
| JP5156997B2 (ja) | Ｉｖ型コラーゲン様免疫活性ペプチド | |
| JP3989837B2 (ja) | 抗ラミニン−１抗体の測定法およびその応用 | |
| JP2003130880A (ja) | 異常型プリオン免疫測定用試薬及びキット並びにそれを用いた異常型プリオンの免疫測定方法 | |
| JP5311117B2 (ja) | 免疫細胞刺激活性を有する機能ペプチド | |
| Laurie et al. | Immunological and partial sequence identity of mouse BM180 with wheat α-gliadin | |
| Bell et al. | Development and Validation of a radioimmunoassay for human secretory ‘pregnancy-associated endometrial α2-globulin’(α2-PEG) and detection in serum during pregnancy | |
| JP3455782B2 (ja) | 強皮症の診断薬 | |
| JP2915530B2 (ja) | ラミニン フラグメント | |
| JP2004257862A (ja) | 重症筋無力症の検査方法及びそのための検査薬 | |
| US20020034739A1 (en) | Peptides characteristic of certain tumors | |
| CN1414871A (zh) | 胎盘人神经激肽b前体 | |
| Lauriel et al. | Substrates and antibodies: Unfractionated gliadin was purchased from Fluka (Ronkonkoma NY). BMS was prepared by EDTA extraction of EHS tumor matrix (3). Preparation of rat anti | |
| WO2004095033A2 (en) | Compositions and methods for accurate early pregnancy diagnosis in ungulates | |
| HK1056692A1 (zh) | 蛋白質 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070524 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080603 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080903 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080908 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090224 |